Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Manegold, C.
Digumarti, R.
Zukin, M.
de Marinis, F.
Mellerngaard, A.
Gandara, D.
Simms, L.
Kaiser, C.
Blatter, J.
Gatzemeier, U.
机构：
[1] Med Ctr Univ Mannheim, Interdisciplinary Thorac Oncol, Mannheim, Germany
[2] Nizams Inst Med Sci, Hyderabad, Andhra Pradesh, India
[3] Natl Canc Inst, Rio De Janeiro, Brazil
[4] San Camillo Forlanini Hosp, Lung Dis Dept, Rome, Italy
[5] Herlev Univ Hosp, DK-2730 Herlev, Denmark
[6] Univ Calif Davis, Davis Canc Ctr, Sacramento, CA 95817 USA
[7] Eli Lilly & Co, Toronto, ON, Canada
[8] Eli Lilly & Co, Indianapolis, IN USA
[9] Eli Lilly Deutschland GMBH, Bad Homburg, Germany
[10] Hosp Grosshansdorf, Grosshansdorf, Germany
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 06期
关键词：
D O I：
10.1016/S1359-6349(07)70101-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1BA
引用
收藏
页码：9 / 9
页数：1
相关论文
共 50 条
  • [1] Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
    Scagliotti, Giorgio
    Purvish, Parikh
    von Pawel, Joachim
    Biesma, Bonna
    Vansteenkiste, Johan
    Manegold, Christian
    Simms, Lorinda
    Posther, Sugarman Katherine
    Obasaju, Coleman
    Blatter, Johannes
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S306 - S306
  • [2] Correlations of biomarker expression and clinical outcome in a large phase III trial of pemetrexed plus cisplatin or gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
    Scagliotti, Giorgio
    Kaiser, Christopher
    Biesma, Bonne
    Manegold, Christian
    Gatzemeier, Ulrich
    Serwatowski, Piotr
    Syrigos, Kostas
    Balint, Beatrix
    Smit, Hans J.
    Vansteenkiste, Johan
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S375 - S375
  • [3] Safety and Resource Utilization by Non-small Cell Lung Cancer Histology Results from the Randomized Phase III Study of Pemetrexed Plus Cisplatin versus Gemcitabine Plus Cisplatin in Chemonaive Patients with Advanced Non-small Cell Lung Cancer
    Novello, Silvia
    Pimentel, Francisco Luis
    Douillard, Jean-Yves
    O'Brien, Mary
    von Pawel, Joachim
    Eckardt, John
    Liepa, Astra M.
    Simms, Lorinda
    Visseren-Grul, Carla
    Paz-Ares, Luis
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (10) : 1602 - 1608
  • [4] Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaive patients with advanced non-small cell lung cancer: A risk-benefit analysis of a large phase III study
    Scagliotti, Giorgio V.
    Park, Keunchil
    Patil, Shekar
    Rolski, Janusz
    Goksel, Tuncay
    Martins, Renato
    Gans, Steven J. M.
    Visseren-Grul, Carla
    Peterson, Patrick
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (13) : 2298 - 2303
  • [5] Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer
    Sandler, AB
    Nemunaitis, J
    Denham, C
    von Pawel, J
    Cormier, Y
    Gatzemeier, U
    Mattson, K
    Manegold, C
    Palmer, MC
    Gregor, A
    Nguyen, B
    Niyikiza, C
    Einhorn, LH
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (01) : 122 - 130
  • [6] Phase I and Pharmacokinetic Study of Pemetrexed plus Cisplatin in Chemonaive Patients with Locally Advanced or Metastatic Malignant Pleural Mesothelioma or Non-Small Cell Lung Cancer
    Dickgreber, Nicolas J.
    Fink, Thomas H.
    Latz, Jane E.
    Hossain, Anwar M.
    Musib, Luna C.
    Thomas, Michael
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (01) : 382 - 389
  • [7] Gemcitabine plus cisplatin versus gemcitabine plus vinorelbine in the treatment of advanced non-small cell lung cancer (NSCLC).
    Zhang, Y
    Zhang, L
    Li, N
    Xu, F
    Pan, ZK
    Guang, ZZ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 702S - 702S
  • [8] Comparison of pemetrexed plus cisplatin versus pemetrexed plus carboplatin in the initial treatment of locally advanced or metastatic non-small cell lung cancer
    Pereira, A. A. R.
    Lessa, R. C.
    Souza, C. E. P.
    Pinto, F. A. I.
    Gagliato, D. M.
    Santos, E. S.
    Fanelli, M. F.
    Rinck, J. A.
    Dettino, A. A.
    Nicolau, U. R.
    Chinen, L. T. D.
    de Lima, V. C. C.
    Pereira, J. R.
    Cruz, M. R. D. S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] Gemcitabine plus cisplatin in advanced non-small cell lung cancer (NSCLC): A phase II study
    Orlandi-Jorquera, L
    Orlandi, F
    Galaz, P
    Gamargo, C
    Salman, P
    Yanez, M
    [J]. ANNALS OF ONCOLOGY, 1998, 9 : 101 - 101
  • [10] Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients
    Zhang, Guan-Zhong
    Jiao, Shun-Chang
    Meng, Zhao-Ting
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2010, 29
12345